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Orthotopic liver transplantation (OLT) and resection are effective treatments for hepatocellular 
carcinoma (HCC).  However, optimizing OLT and limiting HCC recurrence remains a vexing 
problem.  New HCC MELD and allocation algorithms provide greater observation of HCC 
patients, many while receiving local-regional treatments. Potential benefits of local-regional 
treatment for limiting HCC recurrence post-OLT remain incompletely understood.  Therefore we 
aimed to define HCC specific prognostic factors affecting recurrence in a contemporary, multi-
center cohort of HCC patients undergoing OLT and specifically whether local-regional therapies 
limited recurrence.  We identified 441 patients undergoing OLT for HCC at three major 
transplant centers from 2008-2013.  Cox regression was used to analyze covariate-adjusted 
recurrence and mortality rates post-OLT.  “Bridging” or “down-staging” therapy was used in 238 
patients (54%) with transarterial chemoembolization (TACE) being used in 170 (71%) of treated 
patients.  The survival rate post-OLT was 88% and 78% at 1 and 3 years, respectively, with 
HCC recurrence (28% of deaths) significantly increasing mortality rate (HR=19.87, p<0.0001).  
Tumor size, not tumor number, either at presentation or on explant independently predicted 
HCC recurrence (HR 1.36 and 1.73, respectively, p<0.05) with a threshold effect noted at 4.0 
cm size.  Local-regional therapy (TACE) reduced HCC recurrence by 64% when adjusting for 
presenting tumor size (HR 0.36, p<0.05).  Explant tumor size and microvascular invasion 
predicted mortality (HR 1.19 and 1.51, respectively, p<0.05) and pathologic response to therapy 
(TACE or RFA) significantly decreased explant tumor size (0.56-1.62 cm diameter reduction, 
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for HCC recurrence post-OLT.  Local-regional therapy to achieve a pathologic response 





Hepatocellular carcinoma (HCC) continues to be a significant cause of mortality among all other 
solid malignancies and is noted to have the fastest rising incidence and mortality in the U.S. 
among other cancers (1).  HCC is most commonly associated with chronic liver disease or 
cirrhosis, with Hepatitis C virus (HCV) and increasingly non-alcoholic steatohepatitis (NASH) 
being common underlying etiologies (2-4).  Therefore, orthotopic liver transplantation (OLT) has 
been utilized as a means to effectively treat HCC and underlying liver disease. However, 
mortality related to HCC recurrence following OLT has continued to remain significant.  New 
HCC allocation policies have recently been implemented to allow for observation time and 
implementation of local regional therapies for HCC (5).  Outcomes supporting the rationale for 
this policy have shown that a greater duration of time following HCC presentation to OLT is 
protective against mortality following OLT for HCC patients (6-8). 
 
 
While these policies predicated on wait time may improve overall survival for HCC patients 
undergoing OLT, it is still unclear which HCC related factors are most likely to influence HCC 
specific outcomes such as HCC recurrence.  Specifically, the influence of factors related to 
initial HCC presentation, final pathology, and benefits of local-regional therapy such as 
radiofrequency ablation (RFA) or transarterial chemoembolization (TACE) are incompletely 
defined.  Prior studies are either conflicting, lack specific evaluation of these important variables, 
or are under powered to fully evaluate their impact on HCC recurrence following OLT (9-12).  
Commonly utilized databases (e.g., United Network for Organ Sharing (UNOS); Scientific 
Registry of Transplant Recipients (SRTR)) do not provide detailed data with respect to imaging 
(pre- and post- therapy), explant pathology with respect to response, or specific follow up with 
respect to HCC disease recurrence (13-15).  Others studies represent those of single centers 
and while informative, may not be translatable to other centers or lack untreated controls to 
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Both RFA and TACE are known to provide a survival benefit in appropriately selected HCC 
patients based upon HCC tumor stage (17-20).  Furthermore, recent technical advances in how 
TACE is implemented (superselective/selective versus lobar) appear to have improved HCC 
tumor responses in more contemporary studies (21).  However the specific effects of these 




We therefore aimed to better understand and inform future liver allocation policy decisions and 
treatment strategies for HCC patients who are potential OLT candidates.  Thus, we sought to 
more completely identify the effects of disease presentation, treatments, and response to 
treatments on HCC recurrence following OLT.  A multicenter, retrospective cohort of HCC 
patients who underwent OLT at three major transplant centers was examined.  We identified 
which HCC disease factors at initial presentation and the success of local regional therapies 
predicted HCC recurrence following OLT in this multicenter cohort. 
 
Experimental Procedures 
Patient Data Extraction 
The study was conducted after IRB approval at all study sites.  No donor organs were obtained 
from executed prisoners or other institutionalized persons.  Consecutive patients from 2008-
2013 undergoing OLT from three major contemporary transplant centers (University of 
Pennsylvania, University of Michigan, Vanderbilt University) were identified with a diagnosis of 
HCC confirmed on explant pathology.  HCC and liver disease characteristics were determined 
at the time of initial diagnosis of HCC (not formal evaluation of OLT) and at the time of OLT.  
Patients were required to have at least two years of follow up following OLT.  Other diagnoses 
discovered on explant pathology (e.g. cholangiocarcinoma or mixed HCC-cholangiocarcinoma) 
were not included in the cohort.  Patients who underwent local regional treatment were excluded 
from the cohort if there was incomplete treatment details, such as those treated at outside 
centers before presentation.  Patients were not included if their follow up was at a center 
different from that at which they received the OLT.  Patients were listed for OLT at the three 
centers if they met Milan criteria. 
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Patient data included age, sex, liver disease etiology, laboratory Model for End-stage Liver 
Disease (MELD) score, MELD exception status at OLT, listing date, and date of OLT were 
recorded.  HCC presenting tumor burden or stage was determined by examining CT or MRI 
reports and utilizing mRECIST criteria for diagnosis of HCC according to American Association 
for the Study of Liver Diseases (AASLD) guidelines.  Subsequent radiographic reports were 
similarly characterized either following local-regional therapies or at the time closest to OLT, 
depending on time elapsed between initial evaluation or treatment and OLT.  Serum alpha-
fetoprotein (AFP) was also serially determined at presentation and at time of OLT.  Explant 
tumor pathology regarding stage was determined by review of pathology reports and recording 
of maximal tumor size, tumor number, and presence or absence of microvascular invasion.  
Only viable tumor tissue on explant was used to characterize tumor number and size on final 
pathology and thus pathologic stage.  For example, tumors which were completely necrotic 
(100% necrotic), this was equated to a pathologic complete response for which the viable tumor 
diameter would be zero centimeters.  Maximal radiographic and explant pathologic response 
was recorded if local-regional therapy was used.  Responses were characterized as either no 
response, partial response, or complete response. 
 
 
Characteristics regarding presence or absence of local regional therapies were also recorded, 
as were type of therapy used (e.g. TACE, RFA, radiation), individual characteristics of TACE 
(such as selective versus non-selective and type of agent used).  Decisions regarding use of 
local regional therapies were made at the discretion of individual centers and incorporated 
“down-staging” or “bridging” intent as recommended by guidelines using BCLC criteria (18).  
 
Statistical Analysis 
For descriptive analysis of the study cohort, numeric variables were summarized by the sample 
mean, while percentages were used for categorical covariates.  Cox regression was used to 
analyze covariate-adjusted recurrence rates. Death was treated as a competing risk, in the 
sense that the hazard rate for recurrence applied to patients actually at risk for recurrence (i.e., 


















This article is protected by copyright. All rights reserved 
Five different HCC recurrence rate models were fitted.  These were designed to specifically 
isolate whether particular co-variates might influence HCC recurrence. All five models adjusted 
for age, sex, etiology, AFP at OLT, lab MELD at OLT, difference between HCC exception MELD 
score and lab MELD score, and time between initial HCC presentation and OLT.  The individual 
models were characterized by which of the remaining co-variates were included, which 
depended on the particular goal or hypothesis each model was designed to ascertain for an 
effect of a co-variate on HCC recurrence. Specifically, Model 1 focused on initial presentation of 
tumor characteristics (tumor number, size of largest tumor) based on radiography.  Model 2 
instead focused on the same tumor characteristics, but based on information available on 
explant pathology; the model also included an indicator for microvascular invasion (1=yes; 
0=no) and calendar year of diagnosis.  Model 3 evaluated initial tumor characteristics (size, 
number), and also the rate of change of such characteristics, as well as calendar year.  Model 4 
sought to describe the effect of calendar year as a means of describing recurrence trends over 
time.  Due to the lack of adjustment for tumor characteristics or treatment type, the calendar 
year of diagnosis effect estimated through Model 4 is expected to represent the aggregate 
effects of potential changing trends in HCC diagnosis and treatment over time.  Finally, Model 5 
contained co-variates for initial tumor size and number, as well as local regional treatment 
category (RFA, TACE, RFA and TACE, or no treatment). 
 
   
Additional, separate proportional hazards models (Models 1-3, Table 3) were also fitted to the 
outcome of death.  Note that death was not considered censored for patients who experienced 
recurrence.  Death was censored as a separate outcome as patients had deaths as an endpoint 
due to HCC recurrence but also due to non-HCC related causes as well.  Similar to HCC 
recurrence as an outcome, a set of mortality outcome models was fitted with the same co-
variates for Models 1-3 in Table 3.  Separate models for calendar year of diagnosis or 
treatments with mortality as the outcome were not created for mortality analysis. 
 
   
We then fitted an additional separate Cox model for death which included a time-dependent 
binary (0,1) covariate for HCC recurrence. At OLT, all patients had the recurrence covariate set 
to 0; for patients who experienced recurrence, the covariate switched to 1 at the time of 
recurrence and remained at 1 thereafter.  The purpose of this model was to quantify the 
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Additionally we designed linear regression models (Models 1-2, Table 4) to specifically analyze 
the effect of covariates to determine final tumor size on explant pathology.  Co-variates were 
those noted at the time of OLT or initial presentation (Model 1).  Model 2 includes the same co-




Baseline Clinical Characteristics  
A total of 441 transplant patients were identified with a diagnosis of HCC during the interval of 
2008 to 2013 that met the defined inclusion and exclusion criteria.  Their baseline clinical 
characteristics are presented in Table 1.  As expected, the majority of patients were male by a 
nearly 4:1 ratio and hepatitis C was the most common underlying liver disease etiology (69.5%) 
with NASH/cryptogenic and alcohol making up the next most common etiologies, 10.4% and 
8.8%, respectively.  The median follow up for the entire cohort was 47.3 months following 
transplant.  Median AFP at initial presentation was 15.5 ng/mL.  Patients who initially presented 
outside of Milan criteria were 11.4% of the entire cohort.  The mean number of tumors at 
presentation was 1.4 and the mean size at presentation was 2.6 cm.  “Bridging” or “down-
staging” local regional TACE or RFA therapy for HCC was used in 238 (54%) of HCC patients 
and TACE was the most common local-regional therapy used, comprising 170 (71%) of the 
patients treated.  RFA was the next most common modality, comprising 51 (21%) of treated 
patients, and combined TACE and RFA comprised 17 (7%) of treated patients.  Other 
treatments were used rarely in this cohort and included XRT (2 patients), Y90 (1 patient), 
resection (1 patient), and ethanol ablation (2 patients).  Fifteen patients not treated with local 
regional therapy had incidentally discovered HCC on explant of which eleven (73.3%) were 
within Milan criteria.  The mean time following initial HCC presentation to OLT was 11.4 months.  
The survival rate following OLT was 88% and 78% at 1 and 3 years post- OLT, respectively 
(Figure 1).  There was an overall thirty percent mortality rate for the cohort due to all causes 
(133 patients) of which HCC recurrence accounted for 37 of these deaths.  Thus, HCC 
recurrence was the cause for mortality in 28% of patient deaths post-transplant.  
 
Predictors of HCC Recurrence Following Transplant 
Results of the Cox regression models for HCC recurrence rate are in Table 2.  Initial modeling 
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effect on HCC recurrence following OLT.  Incidentally discovered HCC patients (n=15) had an 
HCC recurrence rate of 13.3% (n=2 patients).  The difference between lab MELD score and 
MELD HCC exception score at OLT was a significant predictor of HCC recurrence, such that 
there was 7% decrease in recurrence rate for every lab MELD unit decrease in score.  
Maximum initial tumor size also predicted recurrence, with a calculated 36% increase in the 
HCC recurrence rate for every 1.0 cm increase in tumor size at presentation.  The number of 
HCC tumors at presentation did not significantly predict recurrence.  When explant pathology 
characteristics were substituted into the model for initial tumor presentation (Table 2, Model 2), 
maximum tumor size had an even greater effect on the recurrence rate, with a 73% increase for 
every 1.0 cm increase in tumor size.  The number of tumors found on explant pathology likewise 
had no association with recurrence.  Microvascular invasion identified on explant pathology had 
a significant, 4.54 fold increased risk for HCC recurrence rate following OLT, similar to previous 
studies.  When maximum tumor sizes were taken into account both at initial presentation and at 
the time of OLT (Table 2, Model 3), evidence of progression (increasing tumor size) had the 
most profound effect such that there was a greater than six-fold increase in HCC recurrence 
rate for every 1.0 cm of maximum tumor size progression.  
 
  
To further delineate the effect of explant pathology maximum tumor size on overall HCC 
recurrence rate, we grouped explant maximal tumor sizes into quintiles in order to non-
parametrically assess the effect of tumor size on HCC recurrence rate (Figure 2).  Indeed, the 
effect of maximum tumor size appeared to be non-linear with an apparent threshold effect at 4.0 
cm tumor size to predict recurrence following OLT.  Note that, based on radiographic images at 
initial presentation, the functional relationship between maximum tumor size and HCC 
recurrence rate was less clear and demonstrated no threshold effect (data not shown). 
 
 
The year of HCC diagnosis at initial presentation appeared to effect overall HCC recurrence rate 
following OLT (Table 2, Model 4) when initial presenting tumor characteristics and explant 
findings were removed from the model.  Therefore, HCC recurrence rate decreased by 19% for 
every yearly increment in calendar year of diagnosis.  Thus improving aggregate trends in HCC 
diagnosis and treatment were observed over time for this cohort as this model was not adjusted 
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Factors that predicted a lower HCC recurrence rate, other than smaller tumor size on initial 
presentation or on final pathology and independent of wait time showed that local-regional 
treatment for HCC had a lower predicted HCC recurrence rate (Table 2, Model 5).  Specifically, 
use of TACE reduced HCC recurrence by 64% when adjusting for initial tumor size at 
presentation.  Thus when controlled for initial tumor size, the rate of HCC recurrences per 100 
patient years was reduced from 2.26 recurrences down to 1.72 recurrences with local-regional 
treatment.  Use of RFA did not appear to predict a lower recurrence rate except when 
accounting for radiographic response such that complete absence of a radiographic response 
predicted as much as a 15-fold increase in recurrence rate.  Of note, for patients receiving RFA, 
11.5% had tumors over 3.5 centimeters and 17% had tumors over 3.0 centimeters in size.  
Combined use of RFA and TACE did not reach statistical significance toward reducing HCC 
recurrence rated following OLT.  Other treatment modalities, such as radiation therapy or Y90, 
were used in too small of a sample size to permit analysis. 
 
Factors Associated with Mortality in HCC Patients Following OLT 
Since mortality following OLT can occur due to non-HCC related complications of OLT, we 
sought to identify whether any of the HCC related patient factors were predictive of overall 
mortality. This is important from the perspective that HCC recurrence accounted for the cause of 
death in 28% of all patient deaths post-OLT.  In this multivariate analysis, with death as the 
endpoint, patient factors such as sex and etiology were not predictive for mortality (Table 3).  
However, more advanced age incrementally increased mortality by 16-20% for every five year 
increment (Table 3, Models 1-3).  With respect to HCC related factors, tumor number at initial 
presentation or on pathology, not tumor size at initial presentation, predicted mortality with a 26-
28% increase in death rate per tumor (Table 3, Model 1 and Model 3).  However, based on 
information available at explant pathology (Table 3, Model 2), number of tumors was no longer 
associated with mortality, while maximum tumor size did exhibit a significant association (19% 
increase in mortality rate per cm).  Microvascular invasion was associated with a 51% increase 
in mortality rate, a result which approached but did not attain statistical significance (p=0.07).  
Elevated AFP, particularly greater than 1,000 ng/mL, predicted a higher mortality rate following 
OLT consistent with prior reports showing an effect on HCC recurrence and survival (Table 3, 
Model 1) (23, 24).  Likewise, when AFP increased between initial presentation and time of OLT 
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effect.  The model with HCC recurrence as a time-dependent predictor estimated that HCC 
recurrence increases mortality almost 20-fold (HR=19.87, p<0.0001). 
 
 
Predictors of HCC Explant Pathology 
Since HCC explant pathology, particularly final tumor size, had the most profound effect on 
HCC recurrence rate and is the most potentially modifiable HCC related factor, we sought to 
isolate which factors might overall influence this effect utilizing explant pathology as the 
endpoint.  In Table 4, two linear regression models were designed to evaluate factors affecting 
size of the largest tumor (cm diameter) at explant.  Both models evaluate characteristics at the 
time of OLT. However Model 2 also includes HCC treatment categories. Based on Model 1, the 
significant predictors of tumor size at explant are initial presenting tumor size (positive 
sign=increasing tumor size) and calendar year of diagnosis (negative sign=decreasing tumor 
size).  Model 2, which included treatments, showed increased initial tumor size still significantly 
increases explant size, while explant size still decreased significantly with increasing calendar 
year of diagnosis.  In addition, Model 2 reveals that, relative to no HCC treatment, RFA 
treatment, TACE treatment, or combined RFA and TACE treatment were significantly 
associated with decreased maximal tumor size at explant.  The effect of receiving both RFA and 
TACE was greater than the sum of RFA-alone and TACE-alone, indicating a potential 
synergistic effect on decreasing tumor size at explant. 
 
  
Responses to treatment was classified as either none, partial, or complete.  For the 238 patients 
treated with either RFA or TACE, 50% had a pathologic response at least as favorable as the 
radiographic response. The proportion was slightly higher for patients treated with TACE (at 
52%) compared to those receiving RFA (44%).  
 
Discussion 
Recent studies have led to a change in HCC OLT allocation policy such that an observation 
period is beneficial before OLT once a radiographic diagnosis of HCC is established (5-8).  This 
presumably offers time for 1) the individual HCC biology to declare itself, 2) the radiographic 
stage to be secured, 3) perhaps allow local-regional therapies to identify patients who may or 
may not benefit from OLT, and 4) control disease while other work up and listing proceeds for 
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pathologic and radiographic response in many patients, translating into a survival benefit when 
properly deployed (17, 18, 20).  However, the benefit of local-regional therapy during this 
observation period toward limiting HCC recurrences and thus HCC-related mortality is not 




The present study identified that HCC tumor stage, particularly tumor size was one of the most 
important predictors for both HCC recurrence and mortality.  HCC recurrence was overall the 
most significant predictor for mortality for all patients undergoing OLT for HCC.  We have 
shown, similar to prior studies, that microvascular invasion was one of the most significant 
predictors of HCC recurrence, independent of tumor size (24).  AFP elevation, either at the time 
of transplant or the rate of AFP increase, had no independent effect on HCC recurrence when 
tumor size was included in the multivariate models.  Later calendar year of diagnosis had an 
independent effect of lowering the risk of HCC recurrence.  This is likely related to either 
improved diagnostics over time or the increasing use of local-regional therapies over time in this 
multicenter cohort.  Indeed, inclusion of TACE treatment to the models showed a reduction of 
HCC recurrence when compared to no local-regional treatment and also when initial presenting 
tumor size was included in the model.  This effect of TACE was independent of time from initial 
presentation to the time of OLT (total wait time) (Table 2, Model 5).  Indeed, time from 
presentation of HCC to the time of OLT was not independently predictive in the models for HCC 
recurrence (Table 2) whereas treatment, initial tumor size, tumor progression, and pathologic 
characteristics were independently predictive, suggesting that factors other than “wait time” 
were important for predicting HCC recurrence, particularly tumor stage and treatment.  
 
Use of local-regional therapies increased over time, likely initially affected by lower transplant 
waiting times in the included eras for participating centers during the early part of this cohort.  
Thus the total proportion of patients receiving local-regional treatment was less than a recent 
UNOS data base study (25).  However, the present study had a much longer median follow up 
of 47.3 months, takes into account initial HCC presentation stage, and subsequent 
management.  Prior studies such as the UNOS study assess stage from the time of transplant 
listing filing which is often dependent on many other medical and social factors.  The inclusion of 
a non-treated HCC group also serves as an additional control allowing the current study to 
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Concordant to previous studies, high AFP levels (greater than 1000 ng/mL), along with rate of 
AFP increase, were independently associated with a higher mortality rate (23, 24, 26).  As to 
why lower levels do not correlate independently, this is likely due to AFP (in AFP producing 
HCCs) to correspond to tumor burdens (23) and not necessarily signifying a more aggressive 
HCC.  This has been shown in the resection literature with respect to tumor stage, not AFP, to 
independently predict worse prognoses (27).  A similar relationship of microvascular invasion to 
tumor size has also been noted (23), but presence of microvascular invasion in the current 
study and others was a strong independent risk factor.  Indeed, there was a threshold effect 
(Figure 2) for tumor size diameter of 4.0 cm to increase the risk of HCC recurrence.  Thus tumor 
size, either radiographically or on final pathology, appears to be the best measurable and 
perhaps most modifiable factor toward limiting HCC recurrences with respect to the role of local-
regional therapies.  This suggests that the greatest benefits for local regional therapy may be 
derived when tumors greater than or equal to 4.0 cm are treated such that at least a partial 
response may be generated to reduce tumors to less than 4.0 cm in size. 
 
 
TACE showed a benefit with respect to limiting HCC recurrence on the Cox modeling analysis.  
RFA did not independently predict a decrease in HCC recurrence except in cases where there 
was a complete absence of a response in which these patients carried a 15-fold increase in 
recurrence rate.  The lack of significance for RFA to independently decrease HCC recurrence is 
unclear as RFA has a known, potentially curative, therapeutic benefit when properly applied to 
tumors less than 3.5 cm in size (19, 20).  Since this study is retrospective, possibilities are that 
either 1) RFA may have been applied to tumors at the borderline of this threshold in that 11.5% 
of RFA patients had tumors greater than 3.5 cm and 17% had tumors greater than 3.0 cm, or 2) 
the number of patients receiving RFA alone may have been under powered to detect a 
statistical difference.  Indeed, we did note twelve patients who had RFA alone and had a 
complete pathologic response and no HCC recurrences with four patients dying due to non-
HCC related causes (data not shown).  However, the number was small and failed to be 
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Tumor size on explant was the most significant, objectively measured, tumor related factor 
predicting mortality.  Microvascular invasion approached, but did not quite achieve, statistical 
significance when adjusting for other factors and when tumor size at explant was maintained in 
the model.  This could be due to the known correlation between increasing tumor burden (size) 
and vascular invasion (23, 27).  Given the importance of explant pathology tumor size to predict 
both HCC recurrence and overall mortality, we used this endpoint to assess pathologic 
response of the local-regional therapies.  In this analysis, RFA, TACE, or combination (TACE 
and RFA) versus no treatment had a benefit to reducing tumor burden.  This was independent 
of both calendar year of diagnosis and initial tumor size, suggesting an important effect of local-
regional therapy alone.  In at least 50% of patients where a pathologic response was noted, the 
radiographic response was at least as favorable, suggesting that radiographic response may 
serve as a useful correlate in future studies when trying to evaluate success of local-regional 
therapies and ultimately aiding in determining OLT liver allocation algorithms.  However, these 
correlations would need to be validated in a prospectively designed study.  These findings in our 
present study are in concordance with a recent single center study evaluating the importance of 
pathologic response (vs. lack of a response) to predict less HCC recurrence (16).  However, the 
previously referenced study did not contain an untreated group to serve as a control whereas 
our present study had the advantage of containing an untreated group for comparison. 
 
 
The present study is retrospective and does not allow for independent, prospective review of 
radiographic response and indeed in some patients was not able to be performed in time before 
patients underwent OLT shortly following local-regional therapy.  Likewise, independent, 
prospective pathology review was not possible given the retrospective nature and thus 
assessments of presence or absence of microvascular invasion could be discordant (28).  
Tumor size, either on pathology or on radiographic evaluation, is accepted to be a relatively 
objective measurement in oncologic studies.  Additionally, treatment bias may be present given 
the retrospective nature of this study cohort.  However, the current study does represent 
contemporary practice among three high volume liver transplant centers and detailed data 
regarding tumor characteristics--particularly size, HCC recurrence, and HCC-specific factors 
were able to be reliably obtained with adequate follow up.  While the findings are compelling 
regarding the possible benefits of local-regional therapies to limit HCC recurrence and mortality 
following OLT, prospective studies using consistent treatment algorithms and therapeutic 
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perhaps centralized radiographic review would allow study of whether radiographic response 
could predict overall pathologic response and thus potentially improve stratification of patients 
for OLT and liver allocation.  Thus clear radiographic predictors of pathologic response in 
prospective studies may allow for allocation of livers to patients with active, viable tumor 
burdens whereas patients who exhibit a complete radiographic response may not require 
additional treatments.  
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Figure 1.  Survival rate (event = death) by time (in months) following OLT for HCC. 
 
Figure 2.  Relationship between maximum tumor size on explant pathology and log hazard ratio 
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adjustment covariates) and five categories for tumor size (cm).  Each log HR is plotted against 
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Table 1.  Descriptive statistics on study cohort (n=441 patients). 
Characteristic Median (5th and 95th percentile) or Percent 
Age (years) 56 (44, 68) 
Female 20.9% 
AFP initial presentation (ng/mL) 15.5 (2, 569) 
AFP at OLT (ng/mL) 19 (2, 437) 
Lab MELD at OLT 13 (7, 27) 
MELD Difference (HCC exception – Lab) 9.4 (0, 20) 
Tumor size: initial presentation 2.5 cm (1, 4.9) 
Tumor number: initial presentation 1 (0.8)  
Tumor size: explant pathology 2.0 cm (0, 5) 
Tumor number: explant pathology 1 (1.7) 
Time from initial presentation to OLT 6.5 months (1.4, 39.1) 
Etiology  
    Cryptogenic  5.0% 
    ETOH 8.8% 
    HBV 7.7% 
    HCV 69.0 % 
    NASH 5.4% 
    PSC/PBC/AIH 2.3% 
    Other 1.3% 
Local-regional treatment, n (%) 238 (54%) 
    TACE 170 (71%) 
    RFA 51 (21%) 
    TACE and RFA 17 (7%) 
Death 30.0% 
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Table 2.  Cox regression analysis for HCC recurrence rate following OLT.   
Values presented for each model are hazard ratios (HR), with bold indicating significant 
(p<0.05) and underlined indicating “near-significant” (0.05 < p < 0.10).   
Characteristic Model 1 Model 2 Model 3 Model 4 Model 5 
Age (per 5 years) 0.97 1.01 1.00 0.97 0.98 
AFP at OLT (per 1,000 ng/mL) 1.00 1.00 1.00 1.00 1.00 
AFP: rate of increase -- 0.99 0.99 0.99 -- 
Sex = female 1.34 2.12 1.80 1.24 1.33 
MELD at OLT 0.98 1.01 0.98 1.00 0.97 
MELD Difference 
(exception – lab) 
0.93 1.01 0.95 0.95 0.95 
Tumor size: initial presentation 1.36 -- 1.53 -- 1.45 
Tumor number: initial 
presentation 
0.99 -- 1.06 -- 1.08 
Tumor size: explant pathology -- 1.73 -- --- -- 
Tumor number: explant 
pathology 
-- 1.08 -- -- -- 
Progression (tumor size 
increase) 
-- -- 6.32 -- -- 
Progression (tumor number 
increase) 
-- -- 1.11 -- -- 
Time from initial presentation 
to OLT 
1.01 1.00 1.00 1.00 1.01 
Treatment (vs. no treatment)      
    RFA -- -- -- -- 0.85 
    TACE -- -- -- -- 0.36 
    RFA and TACE -- -- -- -- 0.87 
Calendar year of diagnosis 
(per year) 
-- 0.80 0.87 0.81 -- 
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Table 3.  Cox regression analysis for mortality rate following OLT.  
Values presented for each model are hazard ratios (HR), with bold indicating significant 
(p<0.05) and underlined indicating “near-significant” (0.05 < p < 0.10)   
Characteristic Model 1 Model 2 Model 3 
Age (per 5 yrs) 1.16 1.16 1.19 
AFP at OLT (per 1,000 ng/mL) 1.12 1.00 1.11 
AFP: rate of increase -- 3.42 1.19 
Sex = female 1.45 1.59 1.51 
MELD at OLT 1.03 1.03 1.02 
Difference in MELD 
(exception – lab) 
0.97 0.99 0.96 
Tumor size: initial presentation 1.07 -- 1.06 
Tumor number: initial presentation 1.26 -- 1.28 
Tumor size: explant pathology -- 1.19 -- 
Tumor number: explant pathology -- 1.09 1.28 
Progression (tumor size increase) 1.47 -- 1.47 
Progression (tumor number increase) 1.41 -- 1.41 
Time from initial presentation to OLT 1.01 1.01 1.01 
Treatment (vs. no treatment)    
    RFA -- -- -- 
    TACE -- -- -- 
    RFA and TACE -- -- -- 
Calendar year of diagnosis (per year) -- 1.01 1.05 
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Table 4.  Linear regression analysis for predictors of tumor size at OLT explant 
pathology.  
Values presented for each model represent estimated increase (greater than zero) or decrease 
(less than zero) in maximum tumor size (cm) per unit increase in the covariate as indicated, 
covariate-adjusted. Note that bold indicates significant (p<0.05, with underlined indicating “near-
significant” (0.05 < p < 0.10).   
Characteristic Model 1 Model 2 
Age (per 5 yrs) 0.005 0.006 
AFP at OLT (per 1,000 ng/mL) 0.019 0.075 
Sex = female -0.16 -0.13 
MELD at OLT 0.026 0.014 
Difference in MELD 
(exception – lab) 
-0.024 -0.024 
Tumor size: initial presentation 0.27 0.31 
Time from initial presentation to OLT -0.004 -0.000 
Treatment (vs. none)   
    RFA -- -0.56 
    TACE -- -0.63 
    RFA and TACE -- -1.62 
Calendar year of diagnosis (per year) -0.13 -0.084 
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